National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, December 10, 2001
Sam Perdue (301) 402-1663, sp189u@nih.gov
For a number of years, many scientists have believed that HIV depletes its primary target, CD4+ T cells, by blocking new T-cell production. Two independent studies now challenge that point of view, showing that HIV does not block such production but instead accelerates the division of existing T cells. Following the in
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, December 10, 2001
Sam Perdue (301) 402-1663, sp189u@nih.gov
For a number of years, many scientists have believed that HIV depletes its primary target, CD4+ T cells, by blocking new T-cell production. Two independent studies now challenge that point of view, showing that HIV does not block such production but instead accelerates the division of existing T cells. Following the in
Researchers have found garlic supplements can cause a potentially harmful side effect when combined with a type of medication to treat HIV/AIDS. Investigators from the National Institutes of Health (NIH) observed garlic supplements sharply reduced blood levels of the anti-HIV drug saquinavir . The study re
Researchers have found garlic supplements can cause a potentially harmful side effect when combined with a type of medication to treat HIV/AIDS. Investigators from the National Institutes of Health (NIH) observed garlic supplements sharply reduced blood levels of the anti-HIV drug saquinavir . The study re
Researchers have found garlic supplements can cause a potentially harmful side effect when combined with a type of medication to treat HIV/AIDS. Investigators from the National Institutes of Health (NIH) observed garlic supplements sharply reduced blood levels of the anti-HIV drug saq
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, Dec. 3, 2001
Greg Folkers, (301) 496-2263, gfolkers@nih.gov
A pilot study at the National Institute of Allergy and Infectious Diseases (NIAID) suggests that it may prove feasible for certain people with human immunodeficiency virus (HIV) disease to move from a continuous regimen of anti-HIV therapy to a strategy in which they discontinue and then resume anti-HIV therapy in a pr
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, Dec. 3, 2001
Greg Folkers, (301) 496-2263, gfolkers@nih.gov
A pilot study at the National Institute of Allergy and Infectious Diseases (NIAID) suggests that it may prove feasible for certain people with human immunodeficiency virus (HIV) disease to move from a continuous regimen of anti-HIV therapy to a strategy in which they discontinue and then resume anti-HIV therapy in a pr
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, Dec. 3, 2001
Greg Folkers, (301) 496-2263, gfolkers@nih.gov
A pilot study at the National Institute of Allergy and Infectious Diseases (NIAID) suggests that it may prove feasible for certain people with human immunodeficiency virus (HIV) disease to move from a continuous regimen of anti-HIV therapy to a strategy in which they discontinue and then resume anti-HIV therapy in a pr
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, Dec. 3, 2001
Greg Folkers, (301) 496-2263, gfolkers@nih.gov
A pilot study at the National Institute of Allergy and Infectious Diseases (NIAID) suggests that it may prove feasible for certain people with human immunodeficiency virus (HIV) disease to move from a continuous regimen of anti-HIV therapy to a strategy in which they discontinue and then resume anti-HIV therapy in a pr
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Tuesday, Oct. 9, 2001
Laurie K. Doepel, (301) 402-1663, doepel@nih.gov
National Institute of Allergy and Infectious Diseases (NIAID) researchers at the Dale and Betty Bumpers Vaccine Research Center (VRC) today announced the start of a clinical trial testing the first AIDS vaccine invented at the new facility. The VRC, described as a cross between a biotechnology company and an academic o
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Tuesday, Oct. 9, 2001
Laurie K. Doepel, (301) 402-1663, doepel@nih.gov
National Institute of Allergy and Infectious Diseases (NIAID) researchers at the Dale and Betty Bumpers Vaccine Research Center (VRC) today announced the start of a clinical trial testing the first AIDS vaccine invented at the new facility. The VRC, described as a cross between a biotechnology company and an academic o
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Tuesday, Oct. 9, 2001
Laurie K. Doepel, (301) 402-1663, doepel@nih.gov
National Institute of Allergy and Infectious Diseases (NIAID) researchers at the Dale and Betty Bumpers Vaccine Research Center (VRC) today announced the start of a clinical trial testing the first AIDS vaccine invented at the new facility. The VRC, described as a cross between a biotechnology company and an academic o
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Tuesday, Oct. 9, 2001
Laurie K. Doepel, (301) 402-1663, doepel@nih.gov
National Institute of Allergy and Infectious Diseases (NIAID) researchers at the Dale and Betty Bumpers Vaccine Research Center (VRC) today announced the start of a clinical trial testing the first AIDS vaccine invented at the new facility. The VRC, described as a cross between a biotechnology company and an academic o
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Tuesday, Oct. 9, 2001
Laurie K. Doepel, (301) 402-1663, doepel@nih.gov
National Institute of Allergy and Infectious Diseases (NIAID) researchers at the Dale and Betty Bumpers Vaccine Research Center (VRC) today announced the start of a clinical trial testing the first AIDS vaccine invented at the new facility. The VRC, described as a cross between a biotechnology company and an academic o
National Institutes of Health, National Institute of Allergy and Infectious Diseases - Tuesday, Aug. 14, 2001
Sam Perdue, (301) 402-1663, sp189u@nih.gov
One of HIV s most insidious properties is its ability to influence virtually every part of the human immune system. Antibody-producing B cells, for example, begin to malfunction early after people become infected with HIV, for reasons that have been poorly understood. In a study released today, however, researchers ide
National Institutes of Health, National Institute of Allergy and Infectious Diseases - Tuesday, Aug. 14, 2001
Sam Perdue, (301) 402-1663, sp189u@nih.gov
One of HIV s most insidious properties is its ability to influence virtually every part of the human immune system. Antibody-producing B cells, for example, begin to malfunction early after people become infected with HIV, for reasons that have been poorly understood. In a study released today, however, researchers ide
National Institutes of Health, National Institute of Allergy and Infectious Diseases - Tuesday, Aug. 14, 2001
Sam Perdue, (301) 402-1663, sp189u@nih.gov
One of HIV s most insidious properties is its ability to influence virtually every part of the human immune system. Antibody-producing B cells, for example, begin to malfunction early after people become infected with HIV, for reasons that have been poorly understood. In a study released today, however, researchers ide
National Institutes of Health, National Institute of Allergy and Infectious Diseases - Tuesday, Aug. 14, 2001
Sam Perdue, (301) 402-1663, sp189u@nih.gov
One of HIV s most insidious properties is its ability to influence virtually every part of the human immune system. Antibody-producing B cells, for example, begin to malfunction early after people become infected with HIV, for reasons that have been poorly understood. In a study released today, however, researchers ide
National Institutes of Health, National Institute of Allergy and Infectious Diseases - Tuesday, Aug. 14, 2001
Sam Perdue, (301) 402-1663, sp189u@nih.gov
One of HIV s most insidious properties is its ability to influence virtually every part of the human immune system. Antibody-producing B cells, for example, begin to malfunction early after people become infected with HIV, for reasons that have been poorly understood. In a study released today, however, researchers ide
NIDA Office of Communications and Public Liaison Michelle Muth, Beverly Jackson (301) 443-6245 NIAID Office of Communications and Public Liaison Greg Roa, (301) 402-1663
NIDA Office of Communications and Public Liaison Michelle Muth, Beverly Jackson (301) 443-6245 NIAID Office of Communications and Public Liaison Greg Roa, (301) 402-1663
NIDA Office of Communications and Public Liaison Michelle Muth, Beverly Jackson (301) 443-6245 NIAID Office of Communications and Public Liaison Greg Roa, (301) 402-1663
NIDA Office of Communications and Public Liaison Michelle Muth, Beverly Jackson (301) 443-6245 NIAID Office of Communications and Public Liaison Greg Roa, (301) 402-1663
NIDA Office of Communications and Public Liaison Michelle Muth, Beverly Jackson (301) 443-6245 NIAID Office of Communications and Public Liaison Greg Roa, (301) 402-1663
NIDA Office of Communications and Public Liaison Michelle Muth, Beverly Jackson (301) 443-6245 NIAID Office of Communications and Public Liaison Greg Roa, (301) 402-1663
This information is designed to support, not replace, the relationship that exists between you and your doctor.